Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molgramostim - Reponex Pharmaceuticals

Next Previous
Drug Profile

Molgramostim - Reponex Pharmaceuticals

Alternative Names: Repogel; rhGM-CSF - Reponex Pharmaceuticals; RNX-021

Latest Information Update: 08 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reponex Pharmaceuticals
  • Class Analgesics; Antibacterials; Antibronchitics; Antifibrotics; Antineoplastics; Chemoprotectants; Immunotherapies; Peptides; Recombinant proteins
  • Mechanism of Action Granulocyte macrophage colony stimulating factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Leg ulcer

Most Recent Events

  • 12 Oct 2022 Molgramostim is still in phase II trials for Leg ulcer in Denmark (Topical) (EudraCT2019-001483-30)
  • 10 Jul 2020 Molgramostim - Reponex Pharmaceuticals is available for licensing as of 10 Jul 2020. http://reponex.dk/en/
  • 10 Jul 2020 Reponex Pharmaceuticals has patents pending related to wound healing therapies in Europe, USA, Japan, China, Russia (Reponex Pharmaceuticals website, June 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top